Article
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.
Cancer cell - 9 Sept 2024
McIntyre Caitlin A, Grimont Adrien, Park Jiwoon, Meng Yinuo, Sisso Whitney J, Seier Kenneth, Jang Gun Ho, Walch Henry, Aveson Victoria G, Falvo David J, Fall William B, Chan Christopher W, Wenger Andrew, Ecker Brett L, Pulvirenti Alessandra, Gelfer Rebecca, Zafra Maria Paz, Schultz Nikolaus, Park Wungki, O'Reilly Eileen M, Houlihan Shauna L, Alonso Alicia, Hissong Erika, Church George M, Mason Christopher E, Siolas Despina, Notta Faiyaz, Gonen Mithat, Dow Lukas E, Jarnagin William R, Chandwani Rohit
Abstract excerpt
KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. We examined 1,360 consecutive PDAC patients undergoing surgical resection and find that KRASG12R mutations are enriched in early-stage (stage I) disease, owing not to smaller tumor size but increased node-negativity. KRASG12R tumors are associated...
Topics
Join the communities discussing this publication.